Cargando…

HER2 Positive and HER2 Negative Classical Type Invasive Lobular Carcinomas: Comparison of Clinicopathologic Features

Human epidermal growth factor receptor 2 (HER2) positive (+) classical type invasive lobular carcinoma (cILC) of the breast is extremely rare and its clinicopathologic features have not been well characterized. We compared features of HER2(+) and HER2 negative (−) cILCs. A total of 29 cases were ide...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Lin, Araj, Ellen, Peng, Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161831/ https://www.ncbi.nlm.nih.gov/pubmed/33923191 http://dx.doi.org/10.3390/curroncol28030150

Ejemplares similares

Invasive lobular carcinoma: clinicopathological features and subtypes
por: Danzinger, Sabine, et al.
Publicado: (2021)

Pleomorphic Invasive Lobular Carcinoma of the Breast With Extracellular Mucin and HER2 Amplification
por: Burky, Matthew J, et al.
Publicado: (2020)

Single-Institute Review of HER-2/Neu-Positive Invasive Lobular Breast Carcinoma in an Arab Population
por: Osmani, Asif Husain, et al.
Publicado: (2021)

Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
por: Yang, Liu, et al.
Publicado: (2022)

Can HER2 1+ Breast Cancer Be Considered as HER2-Low Tumor? A Comparison of Clinicopathological Features, Quantitative HER2 mRNA Levels, and Prognosis among HER2-Negative Breast Cancer
por: Shu, Lan, et al.
Publicado: (2022)

The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast
por: Narbe, Ulrik, et al.
Publicado: (2019)

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
por: Morsberger, Laura, et al.
Publicado: (2022)

Comparison of Clinicopathological Features and Treatment Results between Invasive Lobular Carcinoma and Ductal Carcinoma of the Breast
por: Park, Jun Su, et al.
Publicado: (2015)

Clinicopathologic characteristics of HER2-positive pure mucinous carcinoma of the breast
por: Jang, Yunjeong, et al.
Publicado: (2020)

Comparison of the Imaging Features of Lobular Carcinoma In Situ and Invasive Lobular Carcinoma of the Breast
Publicado: (2021)

Clinicopathological features and Borrmann classification associated with HER2-positive in primary gastric cancer
por: Dai, Xiaomin, et al.
Publicado: (2019)

Clinicopathologic features, genomic profiles and outcomes of younger vs. older Chinese hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer patients
por: Wang, Jinhao, et al.
Publicado: (2023)

Effects of Lapatinib on HER2-Positive and HER2-Negative Canine Mammary Carcinoma Cells Cultured In Vitro
por: Leis-Filho, Antonio Fernando, et al.
Publicado: (2021)

Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
por: Grüntkemeier, Lisa, et al.
Publicado: (2022)

Invasive lobular carcinoma with extracellular mucin production and HER-2 overexpression: a case report and further case studies
por: Yu, Jing, et al.
Publicado: (2010)

HER-2 low status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series
por: Rothschild, Harriet T., et al.
Publicado: (2023)

Histologic tumor type as a determinant of survival in hormone receptor-positive, HER2-negative, pT1-3 invasive ductal and lobular breast cancer
por: Göker, Menekse, et al.
Publicado: (2023)

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
por: Loibl, Sibylle, et al.
Publicado: (2022)

Clinicopathological and Molecular Characteristics of Pleomorphic Invasive Lobular Carcinoma
por: Segar, Jennifer M., et al.
Publicado: (2020)

Evaluation of HER2 Positivity Based on Clinicopathological Findings in HER2 Borderline Tumors in Iranian Patients with Breast Cancer
por: Omranipour, Ramesh, et al.
Publicado: (2023)

Clinicopathological features and prognosis of patients with HER2-low breast cancer
por: Yang, Xin, et al.
Publicado: (2023)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
por: Horimoto, Yoshiya, et al.
Publicado: (2022)

Clinicopathologic and genomic features of lobular like invasive mammary carcinoma: is it a distinct entity?
por: Yu, Jing, et al.
Publicado: (2023)

Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer
por: Zhou, Shuling, et al.
Publicado: (2022)

Clinicopathological characteristics and survival outcomes of invasive lobular carcinoma in different races
por: Yang, Li-Yuan, et al.
Publicado: (2017)

Salivary expression of soluble HER2 in breast cancer patients with positive and negative HER2 status
por: Laidi, Fatna, et al.
Publicado: (2014)

HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
por: Kurozumi, Sasagu, et al.
Publicado: (2016)

HER2 expression and relevant clinicopathological features in esophageal squamous cell carcinoma in a Chinese population
por: Rong, Lulu, et al.
Publicado: (2020)

Her2-Positive and Microsatellite Instability Status in Gastric Cancer—Clinicopathological Implications
por: Bermúdez, Ana, et al.
Publicado: (2021)

Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
por: Shikata, Shohei, et al.
Publicado: (2023)

Differences in clinical outcomes between HER2-negative and HER2-positive luminal B breast cancer
por: Kang, Byeongju, et al.
Publicado: (2023)

HER2-positive feline mammary carcinoma
por: Marques, Cláudia, et al.
Publicado: (2016)

Are There More HER2 FISH in the Sea? An Institution’s Experience in Identifying HER2 Positivity Using Fluorescent In Situ Hybridization in Patients with HER2 Negative Immunohistochemistry
por: Suydam, Camille, et al.
Publicado: (2023)

Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas
por: Li, Qingguo, et al.
Publicado: (2011)

Association of Her-2 Expression and Clinicopathological Parameters in Colorectal Carcinoma in Indian Population
por: Hasan, Rameez, et al.
Publicado: (2018)

Amplification and clinicopathological significance of HER-2 in Kazakh esophageal squamous cell carcinoma
por: Muhetaer, Aishanjiang, et al.
Publicado: (2020)

mRNA expression of delta-HER2 and its clinicopathological correlation in HER2-overexpressing breast cancer
por: Wada, Ryuichi, et al.
Publicado: (2016)

Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?
por: Ishimine, Yu, et al.
Publicado: (2015)

Difference of molecular alterations in HER2-positive and HER2-negative gastric cancers by whole-genome sequencing analysis
por: Zhou, Chenfei, et al.
Publicado: (2018)

Clinicopathological factors associated with HER2-positive gastric cancer: A meta-analysis
por: Wang, Hong-Bo, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_6omfhsrbqplnnjjn129pge7808